AIM
CBIO

Alambic Investment Management’s Crescent Biopharma CBIO Stock Holding History

Alambic Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-138
Closed -$42K – 20
2020
Q3 		$42K Buy
+138
New +$52.7K 0.46% 60
2020
Q1 		– Sell
-152
Closed -$80K – 220
2019
Q4 		$80K Sell
152
-265
-64% -$143K 0.07% 253
2019
Q3 		$180K Buy
+417
New +$268K 0.14% 224

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alambic Investment Management's CBIO Position: Q4 2020 in Review

Alambic Investment Management sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 138 shares — an estimated $42K sold.

Alambic Investment Management first reported a position in CBIO in Q3 2019 and held it in 3 quarters. The position peaked at $180K in Q3 2019. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Alambic Investment Management reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 138 Crescent Biopharma shares in Q4 2020, an estimated $42K.
  • Alambic Investment Management first reported a position in Crescent Biopharma in Q3 2019 and held it in 3 quarters.
  • Alambic Investment Management's Crescent Biopharma position peaked at $180K in Q3 2019.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.